Original articleAlimentary tractCombination of Bismuth and Standard Triple Therapy Eradicates Helicobacter pylori Infection in More than 90% of Patients
Section snippets
European Registry on Helicobacter pylori Management
This manuscript is an interim analysis of the current dataset of the European Registry on H pylori Management (Hp-EuReg), an international multicenter prospective noninterventional registry that will last more than 10 years (start date 2013). It has been promoted by the European Helicobacter and Microbiota Study Group (www.helicobacter.org). The study protocol is found in Supplementary Appendix 1.
Study Aim
The Hp-EuReg has as 1 of its aims allowing investigators to propose specific subanalyses of data;
Baseline Characteristics
In the Hp-EuReg, 1221 first-line treatments fitting the regimen (bismuth plus standard triple therapy) have been registered, and 1141 were valid for inclusion analysis after monitoring and quality controls (662 from Spain, 402 from Russia, and 77 from Ukraine). Flow chart diagram is shown in Figure 1. Ages ranged from 18 to 86 years old with a mean age of 49 years and a standard deviation of 15; a total of 59% were women. Indications for treatment were: dyspepsia in 57% (uninvestigated 18%,
Discussion
The present study reports H pylori ITT cure rates with bismuth plus PPI therapy around 90% in a large cohort of naive patients mainly from Spain. Of note, mean cure rates for 10-day triple therapy in Spain were recently estimated to be 70%–80%, similar to those reported in the database of the Hp-EuReg.19 Therefore, addition of bismuth salts to triple therapy in clinical practice resulted in a potential therapeutic gain (10%–20%) in populations with moderate to high clarithromycin resistance.
Acknowledgments
The authors thank the data monitors of the study, Mercedes Ramas (Hospital de La Princesa, Madrid, Spain), and Lorena Lee and Irene Barbado (Fundación Teófilo Hernando, Madrid, Spain) for their large efforts to ensure the validity of the data and quality of their work. They thank Pau Alarcón (Barcelona, Spain) who performed advanced data managing and programming for this project. They also thank the Spanish Association of Gastroenterology and the Scientific Director of the Spanish Association
References (37)
- et al.
IV Spanish Consensus Conference on Helicobacter pylori infection treatment
Gastroenterol Hepatol
(2016) - et al.
Research electronic data capture (REDCap): a metadata-driven methodology and workflow process for providing translational research informatics support
J Biomed Inform
(2009) Acid-related diseases: are higher doses of proton pump inhibitors more effective in the treatment of Helicobacter pylori infection?
Gastroenterol Hepatol
(2008)- et al.
Update on the efficacy of triple therapy for Helicobacter pylori infection and clarithromycin resistance rates in Spain (2007–2012)
Gastroenterol Hepatol
(2013) - et al.
Helicobacter pylori infection
N Engl J Med
(2010) - et al.
Review article: the effectiveness of standard triple therapy for Helicobacter pylori has not changed over the last decade, but it is not good enough
Aliment Pharmacol Ther
(2011) - et al.
Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption
Gut
(2013) - et al.
The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults
Gastroenterology
(2016) - et al.
Management of Helicobacter pylori Infection Maastricht V/ Florence Consensus Report
Gut
(2017) - et al.
Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: systematic review and meta-analysis of efficacy and tolerability
Am J Gastroenterol
(2010)
Triple vs. quadruple therapy for treating Helicobacter pylori infection: a meta-analysis
Aliment Pharmacol Ther
Meta-analysis of bismuth quadruple therapy versus clarithromycin triple therapy for empiric primary treatment of Helicobacter pylori infection
Digestion
Sequential therapy for Helicobacter pylori eradication: a critical review
J Clin Gastroenterol
Review article: non-bismuth quadruple (concomitant) therapy for eradication of Helicobacter pylori
Aliment Pharmacol Ther
Optimizing clarithromycin-containing therapy for Helicobacter pylori in the era of antibiotic resistance
World J Gastroenterol
A report card to grade Helicobacter pylori therapy
Helicobacter
Rational Helicobacter pylori therapy: evidence-based medicine rather than medicine-based evidence
Clin Gastroenterol Hepatol
Infection: Bismuth improves PPI-based triple therapy for H. pylori eradication
Nat Rev Gastroenterol Hepatol
Cited by (65)
Cellular uptake of nickel by NikR is regulated by phase separation
2023, Cell ReportsEmpirical Second-Line Therapy in 5000 Patients of the European Registry on Helicobacter pylori Management (Hp-EuReg)
2022, Clinical Gastroenterology and HepatologyCitation Excerpt :In addition, prescribing clarithromycin in a quadruple regimen (with amoxicillin and bismuth) also might be an option, although there still is limited experience as a rescue treatment.9,30 In the studied cohort, 10-day PPI+clarithromycin+amoxicillin+bismuth was used in a relatively small proportion of patients (5%), achieving 94% effectiveness, and confirming previous encouraging results.30 These results were reinforced in the multivariate analysis, in which longer treatment durations and higher PPI acid inhibition were associated significantly with higher effectiveness, as previously reported.2,9
V Spanish Consensus Conference on Helicobacter pylori infection treatment
2022, Gastroenterologia y HepatologiaBismuth add-on improves the efficacy of 2-week tegoprazan-based triple therapy for first-line Helicobacter pylori eradication: a real-world evidence study
2024, Expert Review of Anti-Infective Therapy
Conflicts of interest These authors disclose the following: Adrian G. McNicholl has received wages from Allergan for formative actions. Ángeles Pérez-Aisa has served as a speaker; and has received wages from Allergan, Norgine, and Casen-Recordati for formative actions and advisory for Shionogi. Javier Molina-Infante has served as a speaker; and has received wages from Allergan, Almirall, and Casen Recordati for formative actions. Javier Alcedo has received wages from Allergan, Almirall, and Casen Recordati for formative actions. Javier P. Gisbert has served as a speaker, a consultant, and advisory member for or has received research funding from Almirall, Nycomed, AstraZeneca, Casen Recordati, and Allergan. The remaining authors disclose no conflicts.